[EN] CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS<br/>[FR] 2,6-DIMÉTHYLFURO[2,3-D]PYRIMIDINES 4-SUBSTITUÉES À CONFORMATION RESTREINTE À TITRE D'AGENTS ANTITUMORAUX
申请人:UNIV HOLY GHOST DUQUESNE
公开号:WO2016100495A1
公开(公告)日:2016-06-23
The present invention provides conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compounds and pharmaceutical compositions comprising these compounds. Preferably, the compounds exhibit dual inhibition of microtubule assembly and receptor tyrosine kinases. Methods of treating cancer comprising administering a therapeutically effective amount of at least one conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compound to a patient is disclosed.
本发明提供构象限制的4-取代2,6-二甲基呋喃[2,3-d]嘧啶化合物和包含这些化合物的制药组合物。优选地,这些化合物表现出微管组装和受体酪氨酸激酶的双重抑制作用。本发明还公开了治疗癌症的方法,包括向患者施用至少一种构象限制的4-取代2,6-二甲基呋喃[2,3-d]嘧啶化合物的治疗有效剂量。